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The effect of angiotensin-converting-enzyme inhibitors on pro-
gression of advanced polycystic kidney disease.
Background. It is not known whether angiotensin-
converting-enzyme (ACE) inhibitors slow the progression of
polycystic kidney disease (PKD). We performed a patient-level
meta-analysis to compare the effect of antihypertensive reg-
imens, including ACE inhibitors, to those without ACE in-
hibitors (controls) on kidney disease progression in patients
with PKD.
Methods. We analyzed a database of 11 randomized con-
trolled trials including 1860 patients with nondiabetic kidney
disease. We compared randomized groups for the decline in
urine protein excretion and kidney disease progression (com-
bined outcome of doubling of baseline serum creatinine or on-
set of kidney failure). We also performed multivariable linear
regression and Cox proportional hazards analyses. Based on
previous findings, we searched for interactions between the
treatment effect (effect of ACE inhibitors vs. controls) and base-
line urine protein excretion in both models.
Results. Eight studies included a total of 142 subjects with
PKD: 68 (48%) were randomized to ACE inhibitors and 74
(52%) were randomized to the control. Baseline mean (SD)
urine protein excretion was 0.92 (1.40) g/day: 1.08 (1.50) g/day
in the ACE inhibitor and 0.76 (1.28) g/day in the control group.
During a mean follow-up of 2.3 years, mean (SD) urine protein
excretion declined by 0.33 (1.11) g/day in the ACE inhibitor
group and increased by 0.19 (0.88) g/day in the control group
(P < 0.001). Kidney disease progression occurred in 50 patients:
20 patients (29%) in the ACE inhibitor group and 30 patients
(41%) in the control group (P = 0.17). ACE inhibitors had a
greater effect on lowering urine protein excretion and slow-
ing kidney disease progression in patients with higher levels of
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baseline urine protein excretion (interaction P < 0.001 and P =
0.03, respectively).
Conclusion. As in other causes of non-diabetic kidney dis-
ease, antihypertensive regimens with ACE inhibitors are more
effective in lowering urine protein excretion in patients with
advanced PKD compared to regimens without ACE inhibitors,
and this benefit is greater in patients with higher levels of base-
line urine protein excretion. The effect of ACE inhibitors to
slow kidney disease progression in PKD is inconclusive.
Polycystic kidney disease (PKD) accounts for 8% to
10% of the burden of kidney failure in the United States
[1]. PKD differs from other causes of nondiabetic kid-
ney disease due to a faster rate of kidney disease pro-
gression, despite lower mean urine protein excretion [2].
While angiotensin-converting enzyme (ACE) inhibitors
have been shown to retard kidney disease progression
in patients with diabetic and nondiabetic kidney disease,
especially in patients with proteinuria [3–5], only a small
number of studies have tested the efficacy of ACE in-
hibitors specifically in patients with PKD [6–10]. The con-
clusions of these studies are limited by small sample sizes,
different outcomes, and conflicting results. Thus, the role
of ACE inhibitors in slowing progression of PKD is not
clear.
Previously we reported a patient level meta-analysis of
11 randomized controlled trails containing 1860 patients
with nondiabetic kidney disease [11]. We found that an-
tihypertensive regimens containing ACE inhibitors were
more effective in slowing the progression of kidney dis-
ease compared to regimens without ACE inhibitors. A
total of 142 (7.8%) of the 1860 patients in our database
had PKD. In this report, we assessed the effect of ACE
inhibitors on progression of PKD. We also sought to de-
termine whether, as in other causes of chronic kidney
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disease, the effect of ACE inhibitors on progress of PKD




The AIPRD Study Group database includes 1860 pa-
tients with nondiabetic kidney disease enrolled in 11 ran-
domized controlled trials of ACE inhibitors to slow the
progression of nondiabetic kidney disease [3, 4, 11–18].
Briefly, studies were identified by searching the MED-
LINE database for English-language studies evaluating
the effect of ACE inhibitors or kidney disease in hu-
mans between 1977 (when ACE inhibitors were approved
for trials in humans) and 1999 (when the database was
closed). A minimum planned follow-up period of 1 year
was required for study inclusion. The database contains
blood pressure, urine protein excretion, serum creatinine,
and onset of kidney failure during 22,610 visits. Inclusion
and exclusion criteria, search strategies for identification
of clinical trials, and details of database formulation have
been described previously [11, 19].
Briefly, we included only randomized trials that com-
pared the effects of antihypertensive agents, including
ACE inhibitors, to regimens without ACE inhibitors in
patients with predominantly nondiabetic kidney disease,
including PKD. Hypertension (systolic blood pressure of
≥140 mm Hg or diastolic blood pressure ≥90 mm Hg or
taking antihypertensive medications) or decreased kid-
ney function was required for entry into all studies. Ex-
clusion criteria common to all studies were acute renal
failure, treatment with immunosuppressive medications,
clinically significant congestive heart failure, obstructive
uropathy, renal artery stenosis, active systemic disease,
insulin-dependent diabetes mellitus, history of trans-
plantation, history of allergy to ACE inhibitors, and
pregnancy. The institutional review board at each partic-
ipating center approved the study, and all patients gave
informed consent. Patients were enrolled between March
1986 and April 1996. All patients were randomized to an-
tihypertensive regimens either with or without ACE in-
hibitors. All patients were followed at a frequency of at
least once every 3 months for the first year and at least
once every 6 months thereafter.
Justification for pooling the 11 clinical trials is based on
the similarity of study designs and patient characteristics.
Justification for pooling placebo-controlled and active-
drug controlled trials is based on the presence of preexist-
ing hypertension and the use of antihypertensive agents
in the vast majority of patients in the control groups in
each clinical trial. Thus, the pooled analysis addresses the
clinically relevant question of the relationship of the level
of blood pressure and urine protein excretion to kidney
disease progression during antihypertensive therapy, ei-
ther with or without ACE inhibitors.
Ascertainment of blood pressure and urine
protein excretion
Blood pressure was measured using a mercury sphyg-
momanometer in nine studies [3–5, 12, 13, 15, 17, 18] (un-
published data [11]) (93% of visits) and calibrated auto-
matic device in two studies [14, 16]. Systolic and diastolic
blood pressure were measured after 5 to 10 minutes’ rest
in the supine position in 10 studies [3–5, 12, 14–18] (un-
published data [11]) and in the sitting position in one
study [13]. Urine protein excretion was reported as total
urine protein excretion in a 24-hour urine. In all studies,
results for urine protein excretion equal to or less than
0.1 g/day were assigned a value of 0.1 g/day (25% of all
patients with PKD). Values greater than 0.1 g/day were
recorded exactly as reported in the study and rounded to
the nearest 0.1 g/day.
Changes in blood pressure and urine protein excre-
tion were computed by subtracting the values at each of
the follow-up visits from the baseline values. For descrip-
tive analyses, follow-up values are the mean of all values
recorded during follow-up.
Outcomes
The primary outcomes were (1) decline in urine pro-
tein excretion from baseline to mean of the follow up
visits, and (2) “kidney disease progression,” defined as
the combined end point of a twofold increase (doubling)
in serum creatinine concentration from baseline values
or development of kidney failure, defined as the onset of
long-term dialysis therapy.
Proteinuria is an independent and modifiable risk fac-
tor for the progression of nondiabetic kidney disease [11,
20]. The benefit of ACE inhibitors on slowing progres-
sion of chronic kidney disease is more pronounced in pa-
tients with proteinuria. This additional benefit of ACE
inhibitors seems to be mediated by a greater reduction
in proteinuria [20]. Thus, we reasoned that reduction in
proteinuria during ACE inhibitor therapy in PKD, as in
other types of nondiabetic kidney disease, may be associ-
ated with a beneficial effect on the progression of chronic
kidney disease.
Doubling of baseline serum creatinine is a well-
accepted “surrogate” outcome of the progression of kid-
ney disease. The addition of this surrogate outcome gives
higher statistical power than analysis using kidney fail-
ure alone. Doublings of baseline serum creatinine were
confirmed by repeat evaluation in only one study, which
used this variable as the primary outcome [18]. Therefore,
we did not require confirmation of the doublings for our
analysis. Reasons for withdrawal were categorized as de-
scribed previously [11, 19].
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Table 1. Study characteristics in the randomized controlled trials included in the pooled analysis
Zuchelli Kamper Brenner et ala Van Essen Hannedouche Ihle Maschio Ruggenenti
Study et al [12] et al [13] et ala et al [14] et al [15] et al [5] et al [18] et ala [3, 4]
Year of publication 1992 1992 1993 1994 1994 1996 1996 1997/1999
Study characteristics
Sample size 121 55 106 103 99 67 562 323
Number of patients with PKD 12 11 15 14 15 10 64 1
Number of visits 1601 193 2333 474 833 588 7456 3292
Number of visits of patients with PKD 165 34 304 63 131 87 836 12
Du ration of follow-up years 2.3 2.2 2.1 3.2 2.1 1.4 2.4 2.1
Study medication in ACE inhibitor groupb C E E E E E B R
Study medication in control groupc S (n) N P S (a) S (a) P P P
Cause of renal disease %
Glomerular disease 26 31 33 26 50 60 34 51
Polycystic kidney disease 10 20 14 14 15 15 11 1
Hypertensive nephrosclerosis 29 0 36 29 7 0 17 13
Tubulointerstitial disease 20 29 5 22 19 2 19 7
Other 15 20 12 9 9 23 19 28
Abbreviations are: PKD, polycystic kidney disease; ACE, angiotensin-converting enzyme; NS, not significant difference.Values indicate percentages or means, as
appropriate.
aBrenner (personal communication), Toto in [4] (personal communication).
bStudy medication in ACE inhibitor group: C, captopril; E, enalapril; CL, cilazapril; B, benazepril; R, ramipril.
cStudy medication in control group: S, specified [(n), nifedipine; (a), atenolol/acebutalol]; N, not specified; P, placebo.
Statistical analyses
We used SAS version 8.0 (SAS Institute, Inc., Cary, NC,
USA) for all statistical analyses. Baseline characteristics
and outcomes were compared between ACE inhibitors
and control groups in patients with PKD using analysis
of variance (ANOVA) or chi-square tests as appropriate.
Linear and Cox proportional hazards regression anal-
yses were performed for the outcomes of decline in urine
protein excretion and kidney disease progression, respec-
tively. For both outcomes, we built multivariable models
with and without adjustment for baseline variables. We
considered the same predictor variables that were used
in the analysis of patients with nondiabetic kidney dis-
ease, as reported previously [11]. Baseline patient char-
acteristics were treatment assignment (ACE inhibitor vs.
control), age (logarithmic transformation), gender, eth-
nicity, systolic blood pressure, diastolic blood pressure,
serum creatinine (reciprocal transformation), and urine
protein excretion. Study characteristics included blind-
ing, the type of antihypertensive regimen in the control
group, the planned duration of follow-up, whether or not
dietary advice was given, and the year of publication. All
baseline variables were introduced as fixed covariates,
and those found to be significantly associated with kid-
ney disease progression in our previous analyses were
retained in the model [11]. Since previously we found an
interaction between treatment effect (effect of ACE in-
hibitor vs. control) and baseline urine protein, this inter-
action was also investigated after adjusting for baseline
characteristics [11].
We also built models incorporating follow-up informa-
tion on blood pressure decline (both models) and decline
in urine protein (Cox model only) as time-dependent co-
variates.
The intention-to-treat principle was followed for com-
parisons of randomized groups. All P values were based
on two-sided tests at < 0.05. The results were expressed
as relative risks with 95% CIs.
RESULTS
Patient and study characteristics
Table 1 shows the study characteristics and patient
characteristics of all studies included in this pooled anal-
ysis of patients with PKD. Eight studies included a total
of 142 patients with PKD. Table 1 shows characteristics
of patients with and without PKD from all 11 studies in
our database.
Comparison of randomized groups among patients
with PKD
Table 2 compares the baseline and follow-up character-
istics of the randomized patients with PKD. Of the 142
patients, 68 (48%) were randomized to the ACE inhibitor
group versus 74 (52%) to the control group. The baseline
characteristics were balanced between the randomized
groups.
During follow-up, the declines in systolic and diastolic
blood pressure were greater by 6.3 and 6.6 mm Hg, re-
spectively, in the ACE inhibitor versus control group (P <
0.001, for each).
Mean (SD) change in urine protein excretion was a
decline of 0.33 (1.11) g/day in the ACE inhibitor group
and an increase of 0.19 (0.88) g/day in the control group
(P < 0.001). A total of 50 (35%) patients reached the
combined outcome of doubling of serum creatinine or
onset of kidney failure: 20 (29%) in the ACE inhibitor
group versus 30 (41%) in the control group (P = 0.17).
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Table 2. Comparison of randomized groups in the polycystic kidney disease (PKD) subgroup
Variable Total ACE inhibitor Control P value
Number of patients% 142 68 (47.9) 74 (52.1)
Baseline characteristics
Male gender% 91 (64.1) 45 (66.1) 46 (62.1) 0.62
Non-black race% 140 (98.6) 67 (98.5) 73 (98.7) 0.95
Hypertension% 142 (100.0) 68 (100.0) 74 (100.0)
Age years (SD) 48 (10.0) 47.8 (9.1) 48.0 (10.8) 0.91
Serum creatinine mg/dL (SD) 3.0 (1.6) 2.9 (1.5) 3.0 (1.7) 0.51
Systolic blood pressure mm Hg (SD) 149 (22) 148 (22) 150 (22) 0.61
Diastolic blood pressure mm Hg (SD) 93 (12) 94 (13) 93 (11) 0.64
Mean urine protein excretion g/day (SD) 0.92 (1.40) 1.08 (1.50) 0.76 (1.28) 0.19
Median urine protein excretion g/day (SD) 0.32 (1.40) 0.43 (1.50) 0.30 (1.28) 0.18
Follow-up characteristics
Decline in systolic blood pressurea mm Hg (SD) 8.1 (19.5) 11.6 (18.5) 5.3 (19.8) <0.001
Decline in diastolic blood pressurea mm Hg (SD) 5.1 (12.5) 8.8 (11.7) 2.3 (12.3) <0.001
Decline in urine protein excretiona g/day (SD) 0.04 (1.03) 0.33 (1.11) −0.19 (0.88) <0.001
Outcomes
Kidney failureb% 25 (17.6) 10 (14.7) 15 (20.3) 0.38
Doubling of baseline serum creatinine% 36 (25.3) 16 (23.5) 20 (27.0) 0.63
Doubling of baseline serum creatinine or kidney failure% 50 (35.2) 20 (29.4) 30 (40.5) 0.17
Death% 4 (2.8) 3 (4.4) 1 (1.3) 0.27
Withdrawals% 31 (21.8) 17 (25.0) 14 (18.9) 0.38
ACE inhibitor side-effectsc 5 (3.5) 2 (2.9) 3 (4.1) 0.72
Nonfatal cardiovascular diseased 0 (0.0) 0 (0.0) 0 (0.0) —
Other nonfatal eventse 8 (5.6) 6 (8.8) 2 (2.7) 0.11
Lost to follow-up or unknown 18 (12.7) 9 (13.2) 9 (12.2) 0.85
Completed study% 57 (40.1) 28 (41.2) 29 (39.2) 0.81
Duration of follow-up years (SD) 2.3 (1.0) 2.2 (1.1) 2.3 (0.9) 0.61
Number of follow-up visits 1551 682 869 0.08
ACE is angiotensin-converting enzyme. Values indicate number of patients (%) or means [standard deviations (SD)], as appropriate. Comparison of variables
between randomized groups was done using the t test for comparison of means and nonparametric two sample test for comparison of median and chi-square test for
discrete variables.
aMean declines in blood pressure and urine protein excretion are calculated by subtracting the respective values at each follow-up visit from the baseline value.
bKidney failure is defined as the onset of long-term dialysis therapy.
cSide-effects possibly due to ACE inhibitors include nonfatal angioedema, hyperkalemia, cough, acute kidney failure, or hypotension.
dNonfatal cardiovascular disease includes myocardial infarction, congestive heart failure, stroke, transient ischemic attacks, and claudication.
eOther non-fatal events include malignancy, pneumonia, cellulitis, headache, gastrointestinal disturbances, and others.
Treatment effect adjusted for baseline
and follow-up characteristics
The unadjusted treatment effect of ACE inhibitors was
a decline (95% CI) of 0.52 (0.36, 0.68) g/day for urine pro-
tein excretion and a relative risk (95% CI) of 0.73 (0.41
to 1.29) for kidney disease progression (combined out-
come of doubling of baseline serum creatinine or onset
of kidney failure) (Table 3).
For the outcome of decline in urine protein excretion,
the treatment effect diminished but remained significant
with a 0.34 (0.21, 0.47) g/day greater reduction in ACE in-
hibitor vs. control group after adjusting for the baseline
covariates, and then also for change in blood pressure
during follow-up (Table 3). This finding suggests that the
beneficial effect of ACE inhibitors is mediated by mech-
anisms in addition to their effect to lower blood pressure.
For the outcome of kidney disease progression, the rel-
ative risk rose and remained nonsignificant in the ACE
inhibitor versus control groups after adjusting (separately
and together) for changes in blood pressure and pro-
teinuria during follow-up (Table 3). The wide confidence
intervals preclude definitive conclusions regarding the ef-
fect of ACE inhibitors on kidney disease progression.
Interactions of treatment effect with baseline
urine protein
There was a significant interaction between baseline
urine protein and treatment effect, with a larger benefit
of ACE inhibitors in patients with higher baseline urine
protein. As shown in Figure 1, the benefit of ACE in-
hibitors increased with baseline urine protein levels for
the outcome of decline in urine protein excretion (inter-
action P = < 0.001) as well as kidney disease progression
(interaction P = 0.03).
DISCUSSION
The results of our pooled analysis show that antihyper-
tensive regimens, including ACE inhibitors, were more
effective in lowering urine protein excretion in patients
with PKD compared to regimens without ACE inhibitors
(Table 3). The effect of ACE inhibitors to lower urine pro-
tein appeared to be due, in part, to mechanisms in addi-
tion to lowering blood pressure (Table 3). In addition, the
effect was significantly greater in patients with higher lev-
els of baseline urine protein excretion (Fig. 1A). We have
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Decline in urine failure relative
Analysis protein g/daya relative risk (95% CI)b
Unadjusted 0.52 (0.36, 0.68) 0.73 (0.41 to 1.29)
Adjusted for baseline
characteristics
0.34 (0.21, 0.47) 0.81 (0.44 to 1.47)
Adjusted for baseline
characteristics and
change in systolic blood
pressure during
follow-up
0.34 (0.21, 0.47) 0.81 (0.44 to 1.47)
Adjusted for baseline
characteristics and
change in urine protein
excretion during
follow-up




and urine protein during
follow-up
N/A 0.91 (0.49 to 1.68)
aDeclines in blood pressure and urine protein excretion were calculated by
subtracting the respective values at each follow-up visit from the baseline value.
bKidney failure is defined as the onset of long-term dialysis therapy.
previously reported similar results in the pooled analysis
of all 1860 patients with nondiabetic kidney disease [20].
When including all patients in the analysis, and adjusting
for baseline covariates, the proteinuria-lowering effect of
ACE inhibitors was greater in the PKD subgroup (N =
142) than in the non-PKD subgroup (N = 1718) (interac-
tion P < 0.001) (data not shown). These results suggest
that ACE inhibitors have beneficial effects on protein-
uria in PKD that are greater than those observed in other
causes of nondiabetic kidney disease.
The benefit of ACE inhibitors on kidney disease pro-
gression in PKD remains inconclusive. The wide con-
fidence intervals for unadjusted and adjusted relative
risks for kidney disease progression (Table 3) reflect the
small number of patients and limited duration of follow-
up. Interestingly, even with the small sample size in this
pooled analysis, the effect of ACE inhibitors on kidney
disease progression appeared significantly greater in pa-
tients with higher levels of baseline urine protein excre-
tion (Fig. 1B), similar to our findings in the pooled analysis
of all 1860 patients with nondiabetic kidney disease [11].
When including all patients in the analysis, and adjust-
ing for baseline covariates, the effect of ACE inhibitors
on kidney disease progression was not statistically signif-
icantly different in the PKD subgroup compared to the
non-PKD subgroup (data not shown). Thus, these data do
not permit definitive conclusions about the effect of ACE
inhibitors in PKD. In our view, large studies of ACE in-
hibitors, or other agents that affect the renin-angiotensin
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Fig. 1. Effect of angiotensin-converting enzyme (ACE) inhibitor treat-
ment. (A) Decline in urine protein excretion in patients with polycystic
kidney disease (PKD). Symbols show the difference in mean decline
in urine protein excretion (95% CI) at various levels of baseline urine
protein excretion in patients with PKD receiving antihypertensive treat-
ment regimens with versus those without ACE inhibitors. Results are
from a multivariable model with covariates include assignment to ACE
inhibitor vs. control group, gender, age, baseline systolic blood pressure,
baseline urine protein excretion, baseline serum creatinine concentra-
tion, and interaction of baseline urine protein excretion and treatment
with ACE inhibitors. (B) Relative risk (95% CI) of kidney disease pro-
gression in patients with PKD. Symbols show the relative risk (95% CI)
of kidney disease progression (the combined outcome of doubling of
baseline serum creatinine or the onset of kidney failure) at various lev-
els of baseline urine protein excretion in patients with PKD receiving
antihypertensive treatment regimens with versus those without ACE in-
hibitors. Results are from a multivariable model with covariates include
assignment to ACE inhibitor vs. control group, gender, age, baseline sys-
tolic blood pressure, baseline urine protein excretion, baseline serum
creatinine concentration, and interaction of baseline urine protein ex-
cretion and treatment with ACE inhibitors.
The clinical significance of the effects of ACE inhibitors
on urine protein in PKD is not clear, since most pa-
tients with PKD have a low level of proteinuria. As in
other causes of nondiabetic kidney disease, hypertension
270 Jafar et al: ACE inhibitors and polycystic kidney disease
and microalbuminuria or proteinuria are associated with
faster kidney disease progression in PKD [2, 21, 22]. Our
results indicate that ACE inhibitors have a small but sig-
nificant effect to lower urine protein excretion in PKD.
The mean level of urine protein excretion in PKD is gen-
erally reported to be approximately less than 0.5 g/day,
and only a minority of patients (<20%) have clinical
proteinuria (>300 mg/day) [22, 23]. Mean urine pro-
tein excretion in patients with PKD in our meta-analysis
(0.92 g/day) is higher than generally reported (16% pa-
tients had urine protein excretion of 2.0 g/day or higher),
probably because of selection bias. It is possible that some
of these individuals had another kidney disease superim-
posed on PKD.
There are a number of possible limitations of our anal-
ysis. First, the studies included in our analysis were not
designed to study the effect of ACE inhibitors on pro-
gression of PKD only. This problem is compounded in
meta-analysis when secondary objectives are analyzed.
However, all studies in our database were designed to
study nondiabetic kidney disease, including PKD. Sec-
ond, one must always question whether it is appropriate
to combine data from different studies. Our evaluation
suggested that the protocols and patients were similar
enough to permit pooling. Third, the power to detect ef-
fects of ACE inhibitors in PKD and to detect interactions
between treatment effects and cause of kidney disease
is limited, since few patients had PKD (142 out of 1860
patients). However, this study represents the largest re-
ported database testing intervention with ACE inhibitors
in patients with PKD. Fourth, a follow-up duration of
2.3 years may be too short for assessing progression of
chronic kidney disease. However, previously we were
able to detect beneficial effect of ACE inhibitors on pro-
gression of chronic kidney disease albeit in a larger sam-
ple of patients [11]. Fifth, as mentioned above, the high
degree of proteinuria in PKD patients in our study may
be due to incurrent illnesses, or superimposition of an-
other cause of kidney disease. However, clinical protein-
uria has been reported in PKD and selection bias could
have resulted due to its greater prevalence in those with
advanced stages of kidney disease. To determine whether
a particular study was contributing to the high overall
mean baseline urine protein excretion of 0.92 g/day, which
is greater than the expected value of under 0.5 g/day in pa-
tients with PKD, we computed the same after excluding
one study at a time, and on a random collective sample of
25 patients from all study centers. The mean values were
between 0.82 to 0.94 g/day, which is within 15% of the
overall mean urine protein excretion of 0.92 g/day. Thus,
we believe that the relatively high baseline urine protein
of 0.92 g/day is a representative mean value for all pa-
tients with PKD in our database. Sixth, measurement of
blood pressure in the supine position deviates from stan-
dardized recommendation of measurement in the sitting
position [24]. However, the position of measurement was
the same during follow-up visits in each study. There-
fore, changes in blood pressure between follow-up and
baseline visits, which we adjusted for in our analyses, are
not expected to be influenced by the position. Thus, we
believe that supine position for measurement of blood
pressure did not bias our findings. Seventh, the study
protocols did not include specific tests for ascertaining
completeness of 24-hour collection. However, detailed
standardized advice regarding 24-hour–timed collection
was given in all eight studies included in this analysis. We
also performed sensitivity analyses after adjusting for the
study terms, and for the outcome of change in predicted
glomerular filtration rate (GFR) [25]. Our main results
remain unchanged (data not shown). Finally, in PKD kid-
ney damage precedes the decline in GFR by many years
[1]. Therefore, any conclusions of this meta-analyis apply
to patients with PKD in the later stages of their disease
only. However, the same limitation applies to most other
studies of progression of nondiabetic kidney disease.
CONCLUSION
ACE inhibitors provide excellent blood pressure con-
trol and lower urine protein in PKD. Further large-scale
studies are required to determine the efficacy of ACE in-
hibitors on progression of PKD. The National Institute
of Diabetes, Digestive, and Kidney Diseases has recently
funded a 7-year trial of antihypertensive agents on the
progression of PKD (url: http://www.pkd.wustl.edu/pkd-
tn/).
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